X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/05/2909179/0/en/Inventiva-provides-an-update-on-its-NATiV3-clinical-program-evaluating-lanifibranor-in-patients-with-MASH-NASH-and-its-financial-position.html
https://www.globenewswire.com/news-release/2024/06/21/2902516/0/en/Description-of-the-Share-Repurchase-Program-Authorised-by-the-Ordinary-General-Meeting-of-20-June-2024.html
https://www.globenewswire.com/news-release/2024/05/30/2890430/0/en/Combined-General-Meeting-of-June-20-2024-Availability-of-the-preparatory-documents.html
https://www.globenewswire.com/news-release/2024/05/30/2890428/0/en/Statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-as-of-May-13-2024.html
https://www.globenewswire.com/news-release/2024/05/22/2886828/0/en/Inventiva-announces-two-scientific-presentations-at-the-EASL-International-Liver-Congress-2024.html
https://www.globenewswire.com/news-release/2024/05/21/2886007/0/en/Inventiva-reports-2024-First-Quarter-Financial-Information-and-provides-a-corporate-update.html
https://www.globenewswire.com/news-release/2024/05/16/2883850/0/en/Inventiva-announces-the-positive-recommendation-of-the-fourth-DMC-of-the-NATiV3-Phase-III-clinical-trial-with-lanifibranor-in-patients-with-MASH-NASH.html
https://www.globenewswire.com/news-release/2024/05/13/2880099/0/en/Inventiva-announces-the-publication-in-Nature-Communications-of-additional-results-from-NATIVE-Phase-IIb-clinical-trial-demonstrating-improvement-of-markers-of-cardiometabolic-heal.html
https://www.globenewswire.com/news-release/2024/03/18/2848135/0/en/Inventiva-announces-positive-results-from-the-Phase-II-LEGEND-Proof-of-Concept-study-combining-lanifibranor-with-empagliflozin-in-patients-with-MASH-NASH-and-T2D.html
https://endpts.com/inventiva-stock-sinks-20-after-serious-adverse-event-in-nash-trial-leads-to-enrollment-pause/
Market Place
Share 
